Immunotherapy Options for Gall Bladder Cancer and Cholangiocarcinoma

tibbionko-17-1-kapak

Serhat SEKMEKa , Burak CİVELEKa
aAnkara Bilkent City Hospital, Department of Medical Oncology, Ankara, Türkiye

Sekmek S, Civelek B. Immunotherapy options for gall bladder cancer and cholangiocarcinoma. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.87-91.

ABSTRACT
Gallbladder cancers (GBC) and cholangiocarcinoma are rare tumors classified as biliary tract cancers (BTC). Until recently, BTC has been treated with surgery, chemotherapy, and radiotherapy. Despite these treatments, overall survival (OS) is only 8-15 months, with 2-year survival rates of 5% in cholangiocarcinoma and 13% in GBC. While minimal survival benefit was observed in BTC with immunotherapy treatments in the first studies, a significant survival increase was achieved by adding durvalumab treatment to gemcitabine cisplatin treatment in the TOPAZ-1 study. Similarly, in the KEYNOTE-966 study, positive results were obtained by adding pembrolizumab treatment to gemcitabine cisplatin treatment. With these results, the benefit of immunotherapy in BTC has been demonstrated, and there are many ongoing studies to achieve even better outcomes in BTCs with the use of both immune checkpoint inhibitors and other immunotherapy options.

Keywords: Gallbladder neoplasms; cholangiocarcinoma; immunotherapy

Referanslar

  1. Patel N, Benipal B. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus. 2019;11(1):e3962. [Crossref]
  2. Rahman R, Simoes EJ, Schmaltz C, Jackson CS, Ibdah JA. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study. Cancer Med. 2017;6(4):874-80. [Crossref]  [PubMed]  [PMC]
  3. Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis. 2010;19(3):285-90.
  4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81. [Crossref]  [PubMed]
  5. Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al.; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690-701. [Crossref]  [PubMed]
  6. Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560-72. [Crossref]  [PubMed]
  7. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593-600. [Crossref]  [PubMed]
  8. Smith GC, Parks RW, Madhavan KK, Garden OJ. A 10-year experience in the management of gallbladder cancer. HPB (Oxford). 2003;5(3):159-66. [Crossref]  [PubMed]  [PMC]
  9. Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652-62. [Crossref]  [PubMed]  [PMC]
  10. Gbolahan O, Hashemi-Sadraei N, O'Neil B. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. J Natl Compr Canc Netw. 2019;17(6):644-8. [Crossref]  [PubMed]
  11. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190-8. [Crossref]  [PubMed]
  12. Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, et al. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020;6(9):1405-9. [Crossref]  [PubMed]  [PMC]
  13. Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen J, Doki Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(4_suppl):387. [Crossref]
  14. Sahai V, Griffith KA, Beg MS, Shaib WL, Mahalingam D, Zhen DB, et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer. 2022;128(19):3523-30. [Crossref]  [PubMed]  [PMC]
  15. Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522-32. Erratum in: Lancet Gastroenterol Hepatol. 2023;8(6):e5. [Crossref]  [PubMed]
  16. Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33 Suppl 9:S1462-3. [Crossref]
  17. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al.; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853-65. Erratum in: Lancet. 2023;402(10406):964. Erratum in: Lancet. 2024;403(10432):1140. [Crossref]
  18. Gutierrez M, Subbiah V, Nemunaitis JJ, Mettu NB, Papadopoulos KP, Barve MA, et al. Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study. J Clin Oncol. 2020. 38(15_suppl):3606. [Crossref]
  19. Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021;131(24):e152670. [Crossref]  [PubMed]  [PMC]
  20. Sahai V, Tran NH, Griffith KA, Zalupski M. A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer. J Clin Oncol. 2019;37(15_suppl):TPS4153. [Crossref]
  21. Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161-9. [Crossref]  [PubMed]
  22. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018;23(12):1407-e136. [Crossref]  [PubMed]  [PMC]
  23. Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, et al. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020;12(11):3404. [Crossref]  [PubMed]  [PMC]
  24. Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother. 2011;34(1):92-9. [Crossref]  [PubMed]
  25. Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005;25(5):3575-9.
  26. Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clin Cancer Res. 2018;24(6):1277-86. [Crossref]  [PubMed]
  27. Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8(1):e000564. [Crossref]  [PubMed]  [PMC]
  28. Yoo C, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Raoul JL, et al. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023;78(3):758-70. [Crossref]  [PubMed]  [PMC]